retatrutide philippines clinical trial UK 2026: Phase 3 Results Retatrutide, an experimental weight-loss drug,

Safety, Side Effects & Approval Both medications can cause gastrointestinal symptoms nausea, vomiting, diarrhoea, and constipation especially early in treatment

GLP-1 receptor agonists are currently used in the treatment of type 2 diabetes and obesity

Patients should not expect dramatic weight loss in the first week , and healthcare professionals typically assess treatment response over a period of months rather than days

However, it may not be suitable for individuals with active cancer or severe health conditions

Doustdar thinks the program could be an opportunity to regain some of the ground Novo's Wegovy shot has lost to Lilly's Zepbound